



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: NAKASHIMA6

In re Application of:)	Conf. No.: 3356
Toshihiro NAKASHIMA et al.)	
)	Art Unit:
)	
Appln. No.: 10/551,263)	Examiner:
)	
Filed: March 28, 2003)	Washington, D.C.
)	
For: MODIFIED SEB AND)	September 18, 2006
PROPHYLACTICS/REMEDIES FOR)	
INNUNOPATHY CONTAINING THE SAME))	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Randolph Building, Mail Stop Amendments
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed

unless specifically required by the Office, a copy of each document listed is attached, except as explained below:

[X] 3. Document AB,AC,AD,AE,AF,AG,AH, is not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states:

[X] An English translation of each document AB,AC,AD,AE,AF,AG,AH (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.


[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Sheridan Neimark
Registration No. 20,520

SN:dac
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\A\Aoyb\Nakashima6\Pto\2006-09-18ids.fee.doc



Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/551,263
Filing Date	March 28, 2003
First Named Inventor	Toshihiro NAKASHIMA
Group Art Unit	
Examiner Name	
Attorney Docket Number	NAKASHIMA6

U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AA	EP 1 055 429 A1	02-15-1999	Juridical Foundation		
	AB	JP 09-110704	04-28-1997	Chemo Sero Therapeut		

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 3

Complete if Known

Application Number	10/551,263
Filing Date	March 28, 2003
First Named Inventor	Toshihiro NAKASHIMA
Group Art Unit	
Examiner Name	
Attorney Docket Number	NAKASHIMA6

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AC	WATANABE, W. "Pharmacotherapy on juvenile rheumatoid arthritis"; Rheumatism; Vol. 36, No. 4, pp.670-675, 1996	
	AD	ICHIKAWA, Y. et al., "Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis"; Vol. 35, No. 4, pp. 663-670, 1995	
	AE	KASHIWAZAKI, S. et al., "Prospective clinical study of the combination therapy of auranofin and methotrexate for rheumatoid arthritis- a multi-center study"; Ryumachi, 1996, Vol. 36, No. 3, pp. 528-544	
	AF	FURUTANI, T. et al., "Adverse effects of low-dose methotrexate on rheumatoid arthritis", Ryumachi, October 1996, Vol. 36, No. 5, pp.746-752	
	AG	YAMAMURA, Y. et al., "Immunodeficiency due to medicament"; Immunological Science; Vol. 9, pp.285-289, 1984	
	AH	TOTOKAWA, S. et al., "Effects of low-dose methotrexate therapy in rheumatoid arthritis: a comparison of three Different dosage regiments"; Ryumachi, October 1997, Vol. 37, No. 5, pp.681-687	
	AI	WHITE, J. et al., "The VB-Specific Superantigen Staphylococcal Enterotoxin B: Stimulation of Mature T Cells and Clonal Deletion in Neonatal Mice"; Cell, Vol. 56, pp.27-35, January 13, 1989	
	AJ	MICUSAN, V.V. et al., "Superantigens of microbial origin"; Seminars in Immunology, Vol. 5, 1993, pp.3-11	
	AK	KIM, C. et al., "Reduction of Lupus Nephritis in MRL/lpr Mice by a Bacterial Superantigen Treatment"; J. Exp. Med, Vol. 174, December 1991, pp.1431-1437	
	AL	ROTT, O. et al., "Protection from experimental allergic encephalomyelitis by application of a bacterial antigen"; International Immunology, Vol. 4, No. 3, pp.347-353	
	AM	KUWAHATA, M. et al., "Age-related occurrence of inhibitory antibodies to streptococcal pyrogenic superantigens"; Acta Paediatrica Japonica, Vol. 38, pp.1-7, 1996	
	AN	ORIGUCHI, T. et al., "Increased levels of serum IgM antibody to staphylococcal enterotoxin B in patients with Rheumatoid arthritis"; Annals of the Rheumatic Diseases, Vol. 54, pp.713-720, 1995	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

